Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: stockdoc77 who wrote (38486)	1/6/2017 10:08:36 PM
From: idahoranch1	8 Recommendations Recommended By captcobra1 chandler27 drtom1234 KeeptheFaith ladyPI and 3 more members Read Replies (1) \| Respond to of 63291

<<The final consideration is what if G does sign a deal before the shareholder meeting? What is the rationale for Venbio at that point? Their interest in IMMU is totally about 132, and if 132 is now controlled by a big pharma, what does it matter who is on the board?>> They didn't initially buy into IMMU to take it over, they liked 132 and felt the stock would respond to more data and its progress towards a deal. Then they got caught in the fIASCO and then the financing. Like me, they had had multiple communications with the company leading up to those events and if anyone here was blindsided by them, anyone with access to management was even more blindsided. Their rationale isn't likely to change, it's to make money with the investment. Little doubt to me they feel they can make more with a business minded BOD, but they likely also feel they can make money if 132 continues to generate good data and marches towards AA. Let's not forget, the phase lll was supposed to start last July (meaning the contract manufacturing would have been up and running with the FDA's blessings), then it was in the fall, then in December, then after the first of the year. I'll be surprised if it happens in the first quarter. To get the best return out of this stock, the street needs to believe the company can deliver. It does not believe that now and even if 132 finally gets off and running and AA looks likely, the stock won't go anywhere near what it would if the street believed in management. Without a change of the BOD, there will continue to be a steep discount in the PPS. THAT is why it matters who is on the board, to them and to ME.

To: stockdoc77 who wrote (38486)	1/6/2017 11:07:03 PM
From: drtom1234	7 Recommendations Recommended By erippetoe idahoranch1 ladyPI patlawche11 plhky3465 and 2 more members Read Replies (1) \| Respond to of 63291

I doubt the rights to 132 in outer mongolia would bring in much, but what about Europe? Japan? Might that bring in 50 million apiece, or more? And since Epratuzumab is continuing to be tested in a variety of liquid malignancies, including an Yttrium-90 labeled version, how can you attribute no value to it; you think there is NO company out there that would be willing to buy Emab, in all it's versions, lock stock and barrel? Vmab clearly has some activity in ITP, you don't think a big pharma could take a chance on that and get it across the line? You don't think the licensing of 130 would bring in any money? The fact is, during the CC, Venbio made no assurances about anything, be that selling shares, or selling rights to the pipeline. They were quite clear that they would need to go in, evaluate what they had, and make decisions. You seem to be attributing plans to venbio that to me, they clearly do not have. As to your final question, I think Lonnie answered just about as I would. The current board needs to go, and the reign of the King Goldenberg and Queen Cindy needs to be over. This company needs to be run like a company, not a fiefdom.